Drug developers Wyeth and Progenics Pharmaceuticals Inc. said Thursday European regulators approved Relistor as a treatment for constipation related to pain drugs taken by terminally ill patients. Read More Permalink[...]
An FDA panel met for two days this week and voted 14 to 2 that diabetes drugs should be subject to additional testing to determine cardiovascular risk, a move that will end countless dollars to drug development. And so this testy exchange took place during the meeting between Steve Nissen, [...]
Posted By:Mike HuckmanAhead of the long holiday weekend I thought this would be as good a time as any to once again go through the "Pharma's Market" mailbag. A couple of blog readers complained about my "short" story about Amgen. Read More Topics:Stock Market | Medicine | PharmaceuticalsSectors:Health Care Equipment [...]
Proposals for tougher heart-risk studies on new Type 2 diabetes drugs weighed heavy on shares of Amylin Pharmaceuticals Inc. and Novo Nordisk AS Thursday, since stricter regulations could mean longer, more costly clinical trials. Read More Permalink[...]
Prescription drug company GlaxoSmithKline says it will appeal a nearly $81 million verdict in a lawsuit that accused it of overcharging Alabama's Medicaid program. A jury in Montgomery on Tuesday found the company liable. It also found Novartis[...]
Pfizer (PFE) has seen its shares sink to a ten year low. Wall Street has punished the stock due to a lackluster first quarter that saw revenues fall 5%, clipping earnings by 15% from $0.48 to $0.41. The shortfall was due to PFE losing its exclusive on both Norvasc and [...]
